Then, antibodies for PD-1 (pembrolizumab and nivolumab) and its ligand PD-L1 (atezolizumab, durvalumab, and Avelumab) have been approved, and widely used for curbing different kinds of cancers 4. This evidence concerns the gene PDCD1 and cancer.